Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026)
Palvella Therapeutics (PVLA) reported Other financing activities of $14.2 million for Q1 2026, up 474800.0% quarter-over-quarter from $3000.0 in Q3 2014.
Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 3 years of Other financing activities data on file, last reported at $14.2 million in Q1 2026.
- Other financing activities for Q1 2026 came in at $14.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (up 284908.0% YoY), and the FY2025 annual result was $154000.0, changed N/A from the prior year.
- Other financing activities climbed to $14.2 million in Q1 2026 per PVLA's latest filing, from $3000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $14.2 million in Q1 2026 and troughed at $14.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.25 Mn |
| Mar 31, 2026 | 14.25 Mn |
| Sep 30, 2014 | 3,000.00 |
| Sep 30, 2014 | 3,000.00 |
| Mar 31, 2014 | 400.00 |
| Mar 31, 2014 | 400.00 |
| Dec 31, 2013 | 1,600.00 |
| Dec 31, 2013 | 1,600.00 |
| Jun 30, 2013 | 474.00 |
| Jun 30, 2013 | 474.00 |